Market Access, Pricing and Reimbursement of Oncology Medicines in the 5EU
All the vital news, analysis, and commentary curated by our industry experts.
Market access of oncology medicines is increasingly challenging due to the rising cost of new and innovative medicines, more stringent scientific and value assessments and economic pressures on national budgets and health systems. Although, 5EU markets have implemented patient access schemed to ensure early access to innovative oncology medicines with high unmet need, the increasing requirements for improved clinical benefits and better cost-effectiveness of medicines has resulted in more stringent pricing and reimbursement of medicines leading to access issues such as delays in patient access due to negotiations.
In this report, GlobalData provides an overview of market access, pricing and reimbursement in the 5EU (France, Germany, Italy, Spain and UK) including key KOL and payers perspectives throughout. KOLs and Payers also provide insights into the market access trends, challenges, drivers and barriers. KOLs and Payers also provide insights on unmet needs in oncology and overall current and future outlook.
GlobalData’s Market Access, Pricing and Reimbursement of Oncology Medicines in the 5EU combines key opinion leader and payer insight with in-house analyst expertise and research to provide an insight-rich look at market access in the 5EU.
Components of the report include:
• Overview of Market Access, Pricing and Reimbursement – What is market access and what are the key concepts and components for pharmaceutical market access of oncology medicines in Europe.
• Market Access, Pricing and Reimbursement in the 5EU – What are the key components of the healthcare systems, pharmaceutical markets and the regulatory framework in each of the 5EU concerning approval, pricing and reimbursement and patient access of cancer medicines in the 5EU
• Market access of new and innovative oncology therapies in the 5EU and related case studies – Which oncology medicines have experience market access issues when entering the EU market and what are the market access challenges and opportunities for new and innovative oncology medicines, immuno-oncology therapies and biosimilars.
• Current and Future Outlook – What are the unmet needs and current issues in oncology, what are the market trends, what changes are expected over the next 5-10 years, what are the drivers and barriers in oncology drug development and market access, what is the current thinking on the high cost and uncertain value of oncology medicines what are the late stage pipeline oncology medicines and their likelihood of experiencing market access issues.
Reasons to Buy
Develop business strategies by understanding the challenges and opportunities for market access in oncology in the 5EU
Reinforce market access capabilities by understanding the key concepts for the scientific and value assessment and appraisal of pharmaceuticals.
Be acquainted with national marketing authorization, HTA, pricing, reimbursement and patient access architectures and policies.
Drive revenues by understanding the unmet needs and market trends for new and innovative medicines likely to impact the oncology market in the future.
Aop Orphan Pharmaceuticals
Industrial Farmaceutica Cantabria
Johnson & Johnson
Pierre Fabre Médicament
Table of Contents
Table of Contents (PowerPoint Deck)
1.1 Table of Contents
1.3 Related Reports
1.4 Upcoming Related Reports
2. Executive Summary
2.1 Key Findings
2.2 KOL and Payer Insights on Market Access, Pricing and Reimbursement in Oncology in the 5EU
3. Overview of Market Access, Pricing and Reimbursement
3.1 Cancer in Europe
3.2 What is Market Access?
3.3 Marketing Authorization
3.4 Marketing Authorization for Early Patient Access
3.5 Cancer Medicines Approved Through EMA Access Schemes
3.6 Health Technology Assessments (HTAs)
3.7 Clinical Endpoints in Oncology
3.8 Scientific and Value Assessment of Oncology Medicines in HTAs
3.9 Patient Reported Outcomes in HTAs
3.10 EU Pricing and Reimbursement – Overview
3.11 EU Pricing and Reimbursement – Pricing Models
3.12 EU Pricing and Reimbursement – Agreements
3.13 Valuing New Medicines
3.14 EU Pricing and Reimbursement – Cost-containment measures
3.15 Cost-containment Measures of Oncology Medicines in the Healthcare System
3.16 The role of the payer in market access
4. Market Access, Pricing and Reimbursement in the 5EU
4.1 Demographic and Socio-economic Factors in Healthcare in the 5EU
4.2 Healthcare Systems of the 5EU
4.3 Health-Related Statistics in the 5EU
4.8 United Kingdom
5. Market access of new and innovative oncology therapies in the 5EU and related case studies
5.1 Overview of Oncology Medicines
5.2 Immuno-oncology Therapies
6. Current and Future Outlook
6.1 Unmet Needs and Current Issues in Oncology
6.2 Market Trends in Oncology
6.3 Market Changes in Oncology Over the Next 5-10 years
6.4 Drivers and Barriers in Oncology Drug Development and Market Access
6.5 The Issue of High Prices and Uncertain Value of Oncology Drugs
6.6 Pipeline Pre-Registration Oncology Drugs in Europe
7.1 Research Methodology
7.2 Primary Research
7.3 About the Authors
7.4 About GlobalData
7.5 Contact Us
Frequently asked questions
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Business Intelligence & Marketing Manager, SAL Heavy Lift
“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.
GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”
Market Analyst & Management, Liebherr-Werk
“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”
Head of Key Accounts, Saab AB
Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.
Marketing Intelligence Manager, Portugal Foods
Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.
Head of Customer Insight and Research, Standard Chartered
Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.
I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.
I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.
Head of Consumer Sensory Insights, Givaudan
“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.
Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”
Senior Account Manager, TSYS
GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise. The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.
I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.
One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.